Eli Lilly and Company (NYSE:LLY) Stock Price Down 0.2%

Eli Lilly and Company (NYSE:LLY - Get Free Report) fell 0.2% during trading on Wednesday . The company traded as low as $772.20 and last traded at $776.55. 650,997 shares changed hands during mid-day trading, a decline of 79% from the average session volume of 3,060,228 shares. The stock had previously closed at $777.77.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on LLY shares. TheStreet upgraded Eli Lilly and Company from a "c+" rating to a "b" rating in a research note on Friday, March 8th. BMO Capital Markets raised their target price on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an "outperform" rating in a research note on Wednesday, May 1st. DZ Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating and set a $820.00 price target on the stock. in a research note on Wednesday, February 21st. Cantor Fitzgerald reissued an "overweight" rating and set a $885.00 price objective (up previously from $815.00) on shares of Eli Lilly and Company in a report on Tuesday, April 30th. Finally, The Goldman Sachs Group increased their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the company a "neutral" rating in a research note on Thursday, April 11th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $757.95.

Eli Lilly and Company Stock Performance

The stock has a market capitalization of $736.56 billion, a PE ratio of 114.14, a PEG ratio of 1.45 and a beta of 0.37. The business's 50 day moving average is $761.22 and its 200 day moving average is $674.88. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating analysts' consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm had revenue of $8.77 billion for the quarter, compared to analysts' expectations of $8.94 billion. During the same quarter in the prior year, the firm posted $1.62 earnings per share. The company's quarterly revenue was up 26.0% on a year-over-year basis. On average, equities research analysts predict that Eli Lilly and Company will post 13.82 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Shareholders of record on Thursday, May 16th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.67%. The ex-dividend date of this dividend is Wednesday, May 15th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 76.58%.

Institutional Investors Weigh In On Eli Lilly and Company

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Versant Capital Management Inc raised its holdings in shares of Eli Lilly and Company by 1.8% in the first quarter. Versant Capital Management Inc now owns 736 shares of the company's stock valued at $573,000 after acquiring an additional 13 shares in the last quarter. Twin Peaks Wealth Advisors LLC increased its position in Eli Lilly and Company by 2.0% during the 1st quarter. Twin Peaks Wealth Advisors LLC now owns 718 shares of the company's stock valued at $559,000 after purchasing an additional 14 shares during the period. Pitti Group Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 0.8% in the 1st quarter. Pitti Group Wealth Management LLC now owns 1,673 shares of the company's stock valued at $1,271,000 after purchasing an additional 14 shares in the last quarter. Ulland Investment Advisors LLC lifted its position in shares of Eli Lilly and Company by 7.0% in the 1st quarter. Ulland Investment Advisors LLC now owns 214 shares of the company's stock worth $166,000 after purchasing an additional 14 shares during the period. Finally, Moseley Investment Management Inc. boosted its stake in shares of Eli Lilly and Company by 0.4% during the first quarter. Moseley Investment Management Inc. now owns 3,890 shares of the company's stock valued at $3,027,000 after purchasing an additional 14 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.